Register Now
STATEMENT OF NEED
Based on a review of the current literature, including national and regional measures, detailed conversations with expert educators at Johns Hopkins, and a survey of potential program participants, this program will address the following core patient gaps:
- Clinicians are unsure about how to best diagnose early/initial P. aeruginosa infection in order to proceed with eradication.
- In the absence of definitive guidance, clinicians are unsure about how the most effective eradication strategies.
- Clinicians are not aware of the most current findings in managing reinfection after P. aeruginosa eradication.
INTENDED AUDIENCE
Pulmonologists, pediatric pulmonologists, gastroenterologists, infectious disease physicians, endocrinologists, respiratory therapists, pediatricians, nurse practitioners, nurses, and other members of the cystic fibrosis team.
ACCREDITATION STATEMENT
PHYSICIANS: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins University school of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
NURSES: The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity.
CREDIT DESIGNATION
PHYSICIANS: The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES: This 1.5 contact hour Educational Activity is provided by the Institute for Johns Hopkins Nursing.
Nursing, Nurse Practitioner and Physician Assistant Credit Reciprocity
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.5 AAPA Category 1 CME Credit(s) for completing this program.
To obtain contact hours, you must complete this Educational Activity and post-test before November 10, 2016.
There are no fees or prerequisites for this activity.
Policy on Faculty and Provider Disclosure:
It is the policy of the Johns Hopkins University School of Medicine that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the course materials.
Course Format
Daniel: A Case for Early Intervention in Pseudomonas aeruginosa Eradication consists of one 90-minute activity certified for a maximum of 1.5 AMA PRA Category 1 Credit(s)™ and delivered as a webcast or podcast. Upon release of this activity, participants will have up to 2 years to complete the one webcast or podcast in order to earn CME credit.
Length of Activity: 1.5 hours
Methods of Participation
There are no fees for participating in this CME activity. To receive credit, participants must (1) read the learning objectives and disclosure statements, (2) complete the educational activity, and (3) complete the post-test and activity evaluation form, including the certificate information section. Physicians must attest to the amount of time they spent on the activity.
Successful Completion
There are no fees for participating in this CME activity. To receive credit, participants must (1) read the learning objectives and disclosure statements, (2) complete the educational activity, and (3) complete the post-test and activity evaluation form, including the certificate information section. Physicians must attest to the amount of time they spent on the activity.
Enduring Materials
Date of release: 11/10/14
Expiration date: 11/9/16
LEARNING OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:
- Evaluate the pros and cons of early P. aeruginosa eradication.
- Summarize the current evidence basis and expert opinion informing eradication best practices.
- Encapsulate key data from significant eradication trials including ELITE, EPIC, and ALPINE.
- Incorporate evidence-based strategies to assess and improve eradication in the early stages of P. aeruginosa infection.
STATEMENT OF RESPONSIBILITY
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
CONFIDENTIALITY DISCLAIMER FOR CME CONFERENCE ATTENDEES
I certify that I am attending a Johns Hopkins University School of Medicine CME activity for accredited training and/or educational purposes.
I understand that while I am attending in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person's health or treatment that identifies the person.
I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.
I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.
"The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is attending for training, education and/or observation purposes only."
For CME Questions, please contact the CME Office
(410) 955-2959 or e-mail cmenet@jhmi.edu.
For CME Certificates, please call (410) 502-9634.
Johns Hopkins University School of Medicine
Johns Hopkins University School of Medicine Office of Continuing Education
Turner 20/720 Rutland Avenue
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03) (Updated 4/09 and 3/14)
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
Supported by an educational grant from Gilead Sciences, Inc.
FACULTY AND PROVIDER DISCLOSURE
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation.
THE FOLLOWING RELATIONSHIPS HAVE BEEN REPORTED FOR THIS ACTIVITY
PLANNER:
| Name | Relationships |
|---|---|
| Michael P. Boyle, MD, FCCP | Scientific Advisory Board: Gilead Sciences, Inc., Novartis Pharmaceuticals, Savara Pharmaceuticals, Vertex Pharmaceuticals Incorporated Principal Investigator: Vertex Pharmaceuticals Incorporated |
No other planners have indicated that they have any financial interests or relationships with a commercial entity.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
SPEAKERS:
| Name | Lecture Title | Relationships |
|---|---|---|
| Harm Tiddens, MD | Approaches to Treating this Patient |
Grant/Research Funding: Gilead Sciences, Inc., Chiesi Farmaceutici Honoraria: Gilead Sciences, Inc. |
| Claire Wainwright, MBBS, MRCP, FRACP, MD | What to do When Reinfection Occurs |
Grant/Research Funding: Novartis Pharmaceuticals, Vertex Pharmaceuticals Incorporated Advisory Board: Vertex Pharmaceuticals Incorporated Honoraria: Vertex Pharmaceuticals Incorporated |
OFF-LABEL PRODUCT DISCUSSION
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:
| Name | Lecture Title(s) | Product |
|---|---|---|
| Peter J. Mogayzel, Jr, MD, PhD | Q&A | tobramycin inhalation solution, aztreonam inhalation solution, colistin, ciprofloxacin |
| Margaret Rosenfeld, MD, MPH | Why Eradication – A Clinical Perspective; Q&A | tobramycin inhalation solution, aztreonam inhalation solution, colistin, ciprofloxacin |
| Harm Tiddens, MD | Approaches to Treating this Patient; Q&A | tobramycin inhalation solution, aztreonam inhalation solution, colistin, ciprofloxacin |
| Donna Peeler, RN, BSN | Q&A | tobramycin inhalation solution, aztreonam inhalation solution, colistin, ciprofloxacin |
| Claire Wainwright, MBBS, MRCP, FRACP, MD | What to do When Reinfection Occurs; Q&A | tobramycin inhalation solution, aztreonam inhalation solution, colistin, ciprofloxacin |
Disclaimer
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of the Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Internet CME Policy
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet-based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine's CME program. CME collects only the information necessary to provide you with the services that you request.
Hardware & Software Requirements
PC: Internet Explorer (v7 or greater), or Firefox
MAC: Safari
Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.